Autoimmune events during interferon beta-1b treatment for multiple sclerosis

Journal of the Neurological Sciences

Volumn 162, Issue 1, 1999, Pages 74-83

  Durelli, L ^a   Ferrero, B ^a   Oggero, A ^a   Verdun, E ^a   Bongioanni, M R ^a   Gentile, E ^a   Isoardo, G L ^a   Ricci, A ^a   Rota, E ^a   Bergamasco, B ^a   Durazzo, M ^a   Saracco, G ^b   Biava, M A ^a   Brossa, P C ^b   Giorda, L ^b   Pagni, R ^b   Aimo, G ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Autoantibodies; Autoimmune events; Autoimmune liver dysfunction; Autoimmune thyroid dysfunction; Interferon beta treatment; Multiple sclerosis; Side effects

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; INTERFERON BETA SERINE; LEVOTHYROXINE; METHYLPREDNISOLONE; SMOOTH MUSCLE ANTIBODY; THIAMAZOLE; THYROID ANTIBODY;

ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HASHIMOTO DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER DISEASE; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AUTOANTIBODIES; AUTOIMMUNE DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; RADIOLIGAND ASSAY; RECOMBINANT PROTEINS; RECURRENCE; THYROID FUNCTION TESTS; TIME FACTORS;

EID: 0032945247     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(98)00299-8     Document Type: Article

References (69)

1. Alexander G.J.M., Brahm J., Fagan E.A., Smith H.M., Daniels H.M., Eddleston A.L.W.F., Williams R. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet. ii:1987;66-68.
2. Barned S., Goodman A.D., Mattson D.H. Frequency of anti-nuclear antibodies in multiple sclerosis. Neurology. 45:1995;384-385.
3. Burman P., Totterman T.H., Oberg K., Karlsson F.A. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab. 63:1988;1086-1090.
4. Cirelli R, Herne KB, McCrary ML, Tyring SK. Adverse effects of interferons. In: Reder AT, editor. Interferon therapy of multiple sclerosis. New York: Dekker, 1997:445-478.
5. Dayal A.S., Jensen M.A., Lledo A., Arnason B.G.W. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology. 45:1995;2173-2177.
6. De Keyser J. Autoimmunity in multiple sclerosis. Neurology. 38:1988;371-374.
7. DeMaeyer EM, De Maeyer-Guignard J. Modulation of the expression of the major histocompatibility antigens. In: DeMaeyer EM, De Maeyer-Guignard J, editors. Interferons and other regulatory cytokines. New York: Wiley, 1988:174-193.
8. Deutsch M., Dourakis S., Manesis E.K., Gioustozi A., Hess G., Horsch A., Hadziyannis S. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alpha therapy. Hepatology. 26:1997;206-210.
9. Dore-Duffy P., Donaldson J.O., Rothman B.L., Zurier R.B. Antinuclear antibodies in multiple sclerosis. Arch Neurol. 39:1982;504-506.
10. Dorman J.S., LaPorte R.E., Stone R.A., Trucco M. Worldwide differences in the incidence of type I diabetes are associated with amino acid variation at position 57 of HLA-DQbeta chain. Proc Natl Acad Sci USA. 87:1990;7370-7374.
11. Durelli L., Bongioanni M.R., Cavallo R.et al. Chronic systemic high-dose recombinant interferon alpha-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology. 44:1994;406-413.
12. Durelli L., Bongioanni M.R., Ferrero B.et al. Long term recombinant interferon alpha treatment in MS with special emphasis to side effects. Multiple Scler. 1:1996;366-371.
13. Durelli L. Recombinant interferon-alpha in the treatment of multiple sclerosis. Effects on exacerbation rate, magnetic resonance imaging of lesion activity, and cytokines. In: Reder AT, editor. Interferon therapy of multiple sclerosis. New York: Dekker, 1997:307-341.
14. Durelli L., Bongioanni M.R., Ferrero B., Oggero A., Marzano A., Rizzetto M. Interferon treatment for multiple sclerosis: autoimmune complications may be lethal. Neurology. 50:1998;570-571.
15. Fentiman I.S., Balkwill F.R., Thomas B.S., Russel M.J., Todd I., Bottazzo G.F. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol. 24:1988;1299-1303.
16. Finkelman F.D., Svetic A., Gresser I., Snapper C., Holmes J., Trotta P.P., Katona I.M., Gause W.C. Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice. J Exp Med. 174:1991;1179-1188.
17. Garcia-Buey L., Garcia-Monzon C., Rodriguez S.et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology. 108:1995;1770-1777.
18. Hafler D.A., Weiner H.L. MS: a CNS and systemic autoimmune disease. Immunol Today. 10:1989;104-107.
19. Hartung H.P. Pathogenesis of inflammatory demyelination: implications for therapy. Curr Opin Neurol. 8:1995;191-199.
20. Heathcote E.J. Autoimmune hepatitis and chronic hepatitis C: latent or initiated by interferon therapy? Gastroenterology. 108:1995;1942-1944.
21. Hohlfeld R., Meinl E., Weber F.et al. The role of the autoimmune T lymphocytes in the pathogenesis of multiple sclerosis. Neurology. 45(6):1995;S33-S38.
22. Hoofnagle J.H., Di Bisceglie A.M., Waggoner J.G., Park Y. Interferon alpha for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology. 104:1993;1116-1121.
23. Huber M., Bamborschke S., Assheuer J., Heiss W.-D. Intravenous natural beta interferon treatment of chronic exacerbating-remitting multiple sclerosis: clinical response and MRI/CSF findings. J Neurol. 235:1988;171-173.
24. Ioppoli C., Meucci G., Mariotti S., Martino E., Lippi A., Gironelli L., Pinchera A., Muratorio A. Circulating thyroid and gastric parietal cell autoantibodies in patients with multiple sclerosis. Ital J Neurol Sci. 11:1990;31-36.
25. Iwasaki Y., Kinoshita M. Thyroid function in patients with multiple sclerosis. Acta Neurol Scand. 77:1988;269.
26. Jacobs L.D., Cookfair D.L., Rudick R.A.et al. and the Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 39:1996;285-294.
27. Janssen H.L.A., Brouwer J.T., Nevens F., Sanchez-Tapias J.M., Craxi A., Hadziyannis S. Fatal hepatic decompensation associated with interferon alpha. Br Med J. 306:1993;107-108.
28. Johnson P.J., McFarlane I.G. Meeting report: international autoimmune hepatitis group. Hepatology. 18:1993;998-1005.
29. Kinnunen E., Timonen T., Pirttila T., Kalliomaki P., Ketonen L., Matikainen E., Sepponen R., Juntunen J. Effects of recombinant alpha-2b interferon therapy in patients with progressive MS. Acta Neurol Scand. 87:1993;457-460.
30. Kraiem Z., Sobel E., Sadeh O., Kinarty A., Lahat N. Effects of gamma-interferon on DR antigen expression, growth, 3,5,3′-triiodothyronine secretion, iodide uptake, and cyclic adenosine 3′,5′-monophosphate accumulation in cultured human thyroid cells. J Clin Endocrinol Metab. 71:1990;817-824.
31. Kung A.W.C., Ma L., Lau K.S. The role of interferon-gamma in lymphocytic thyroiditis: its functional and pathological effect on human thyrocytes in culture. Clin Exp Immunol. 87:1992;261-265.
32. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
33. Larsen PR, Ingbar SH. The thyroid gland. In: Wilson JD, Foster DW, editors. Williams textbook of endocrinology. Philadelphia: Saunders, 1992:357-487.
34. Lisker-Melman M., Di Bisceglie A.M., Usala S.J., Weintraub B., Murray L.M., Hoofnagle J.H. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alpha. Gastroenterology. 102:1992;2155-2160.
35. Lublin F.D., Whitaker J.N., Eidelman B.H., Miller A.E., Arnason B.G.W., Burks J.S. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 46:1996;12-18.
36. Marazuela M., Garcia-Buey L., Gonzales-Fernandez B.et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol. 44:1996;635-642.
37. Marcellin P., Monteau M., Renard P., Grynblat J.M., Linhart N.C., Bardet P., Bok B., Benhamou J.-P. Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C. Gut. 33:1992;855-856.
38. Marcellin P., Pouteau M., Benhamou J.P. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol. 22:1995;364-369.
39. Marrosu M.G., Muntoni F., Murru M.R.et al. HLA-DQB1 genotype in Sardinian multiple sclerosis: evidence for a key role of DQB1*0201 and*0302 alleles. Neurology. 42:1992;883-886.
40. Martin S., Kardorf J., Schulte B.et al. Autoantibodies to the islet antigen ICA69 occur in IDDM and in rheumatoid arthritis. Diabetologia. 38:1995;351-355.
41. Midgard R., Gronning M., Riise T., Kvale G., Nyland H. Multiple sclerosis and chronic inflammatory diseases. Acta Neurol Scand. 93:1996;322-328.
42. Neilley L.K., Goodin D.S., Goodkin D.E., Hauser S.L. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology. 46:1996;552-554.
43. Okanoue T., Sakamoto S., Itoh Y.et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 25:1996;283-291.
44. Oksenberg JR, Hauser SL. Pathogenesis of multiple sclerosis: relationship to therapeutic strategies. In: Goodkin DE, Rudick RA, editors. Multiple sclerosis. Advances in clinical trial design, treatment and future perspectives. London: Springer, 1996:17-46.
45. Panitch H.S., Francis G.S., Hooper C.J., Merigan T.C., Johnson K.P. Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon. Ann Neurol. 18:1985;434-438.
46. Panitch H.S., Hirsch R.L., Schindler J., Johnson K.P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 37:1987;1097-1102.
47. Panitch H.S. Interferons in multiple sclerosis. A review of the evidence. Drugs. 44:1992;946-962.
48. Pichert G., Jost L.M., Zobeli L., Odermatt B., Pedio G., Stahel R.A. Thyroiditis after treatment with interleukin-2 and interferon alpha-2a. Br J Cancer. 62:1990;100-104.
49. Poser C.M., Paty D.W., Scheinberg L.et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 13:1983;227-231.
50. Preziati D., La Rosa L., Covini G.et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol. 132:1995;587-593.
51. Ransohoff R.M., Tuohy V.K., Barna B.P., Rudick R.A. Monocytes in active multiple sclerosis: intact regulation of HLA-DR density in vitro despite decreased HLA-DR density in vivo. J Neuroimmunol. 37:1992;169-176.
52. Rice G.P.A., Woelfel E.L., Talbot P.J., Braheny S.L., Sipe J.C., Knobler R.L., Merigan T.C., Oldstone M.B.A. Immunological complications in multiple sclerosis patients receiving interferon. Ann Neurol. 18:1985;439-442.
53. Ronnblom L.E., Alm G.V., Oberg K.E. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med. 115:1991;178-183.
54. Roti E., Minnelli R., Giuberti T.et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med. 172:1996;482-487.
55. Rudge P., Miller D., Crimlisk H., Thorpe J. Does interferon beta cause initial exacerbation of multiple sclerosis? Lancet. 345:1995;580.
56. Saracco G., Touscoz A., Durazzo M.et al. Autoantibodies and response to alpha-interferon in patients with chronic viral hepatitis. J Hepatol. 11:1990;339-343.
57. Schwid S.R., Goodman A.D., Mattson D.H. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b. Arch Neurol. 57:1997;1169-1170.
58. Seyfert S., Klapps P., Meisel C., Fischer T., Junghan U. Multiple sclerosis and other immunologic diseases. Acta Neurol Scand. 81:1990;37-42.
59. Sheremata W.A., Taylor J.R., Elgart G.W. Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b. N Engl J Med. 8:1995;1584.
60. Strassburg C.P., Manns M.P. Autoimmune hepatitis versus viral hepatitis C. Liver. 15:1995;225-232.
61. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
62. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
63. Vallisa D., Cavanna L., Berte R., Merli F., Ghisoni F., Buscarini L. Autoimmune thyroid dysfunction in hematologic malignancies treated with alpha-interferon. Acta Haematol. 93:1995;31-35.
64. Vial T., Descotes J. Clinical toxicity of the interferons. Drug Saf. 10:1994;115-150.
65. Vial T., Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology. 105:1995;31-57.
66. Wang C., Crapo L.M. The epidemiology of thyroid disease and implication for screening. Endocrinol Metab Clin North Am. 26:1997;189-217.
67. Watanabe U., Hashimoto E., Hishamitsu T., Obata H., Hayashi N. The risk factors for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol. 89:1994;399-403.
68. 125I incorporation and thyroid hormone release by human thyroid follicles in vitro. J Clin Endocrinol Metab. 77:1993;1439-1441.
69. Yoshikawa M., Fukui H., Tsujii T. Immunological adverse effects of interferon treatment. Clin Immunother. 4:1995;361-375.